medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2013, Número 2

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2013; 11 (2)


Prolactina y autoinmunidad en piel

Solís AMP, Rodríguez GG, Vega MME

Idioma: Español
Referencias bibliográficas: 50
Paginas: 148-154
Archivo PDF: 198.98 Kb.


RESUMEN

La prolactina (PRL) es una hormona conocida por su función en la reproducción y la lactancia, pero en años recientes se ha estudiado su relación con el folículo piloso y la piel, ya que ésta es el órgano endocrino periférico más grande y actúa como vínculo entre los sistema inmunológico y neuroendocrino.
El presente artículo describe aspectos fundamentales de la biología de prolactina, y hace una revisión de la literatura sobre algunas enfermedades autoinmunológicas y el papel de PRL en su patología.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Shelly S, Boaz M, Orbach H. “Prolactin and autoimmunity”. Autoimmun Rev 2012; 11(6-7): A465-A470.

  2. Chikanza IC. “Prolactin and neuroimmunomodulation: in vitro and in vivo observations”. Ann N Y Acad Sci 1999; 876: 119-130.

  3. Rivero A, García-Calvo A. “Biochemical diagnosis of monomeric hyperprolactinemia”. An Sist Sanit Navar 2011; 34: 145-152.

  4. Peeva E, Zouali M. “Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes”. Immunol Lett 2005; 101: 123-143.

  5. Freeman ME, Kanyicska B, Lerant A, Nagy G. “Prolactin: structure, function, and regulation of secretion”. Physiol Rev 2000; 80: 1523-1631.

  6. Berinder K, Akre O, Granath F, Hulting AL. “Cancer risk in hyperprolactinemia patients: a population-based cohort study”. Eur J Endocrinol 2011; 165: 209-215.

  7. Reuwer AQ, van Ejik M, Houttujin-Bloemendaal FM, van der Loos CM, Claessen N, Teeling P, et al. “The prolactin receptor is expressesd in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis?” J Endocrinol 2011; 208: 107-117.

  8. Moreno J, Varas A, Vicente A, Zapata AG. “Role of prolactin in the recovered T-cell development of early partially decapitated chicken embryo”. Dev Immunol 1998; 5: 183-195.

  9. Vera-Lastra O, Jara LJ, Espinoza LR. “Prolactin and autoimmunity”. Autoimmun Rev 2002: 1: 360-364.

  10. Saha S, González J, Rosenfeld G, Keiser H, Peeva E. “Prolactin alters the mechanisms of B cell tolerance induction”. Arthritis Rheum 2009; 60: 1743-1752.

  11. Matera L, Mori M, Galetto A. “Effect of prolactin on the antigen presenting function of monocyte-derived dentritic cells”. Lupus 2001; 10: 728-734.

  12. Krause I, Blumenfeld Z, Malchinsky M, Cohen S, Blank M, Eldor A, et al. “Anti-endothelial cell antibodies in the sera of hyperprolactinemic women”. Lupus 1998; 7: 377-382.

  13. Jara LJ. Lavalle C, Fraga A, Gómez-Sánchez C, Silveira LH, Martínez- Osuna P, et al. “Prolactin, immunoregulation and autoinmune diseases”. Semin Arthritis Rheum 1991; 20: 273-284.

  14. Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, et al. “Guidelines for the diagnosis and treatment of hyperprolactinemia”. J Reprod Med 1999; 44: 1075-1084.

  15. Hoffman Ar, Melmed S, Schlechte J. “Patient guide to hyperprolactinemia diagnosis and treatment”. J Clin Endocrinol Metab 2011; 96: 35A-36A.

  16. Jara LJ, Vera-Lastra O, Miranda JM, Alcala M, Álvarez-Nemegyei J. “Prolactin in human systemic lupus erythematosus”. Lupus 2001, 10: 748-756.

  17. Rovenský J, Juránková E, Rauová L et al. “Relationship between endocrine, immune, and clinical variables in patients with systemic lupus erythematosus”. J Rheumatol 1997; 24: 2330–2334.

  18. McMurray RW, Allen SH, Braun AL, Rodríguez F, Walker SE. “Longstanding hyperprolactinemia associated with systemic lupus erythematosus: possible hormonal stimulation of an autoimmune disease”. J Rheumatol 1997; 21: 843–850.

  19. Reuman PD. “First reported pediatric case of systemic lupus erythematosus associated with prolactinoma”. Arthritis Rheum 2004; 50: 3616-3618.

  20. Pacilio M, Migliaresi S, Meli R, Ambrosone L, Bigliardo B, Di Carlo R. “Elevated bioactive prolactin levels in systemic lupus erythematosus— association with disease activity”. J Rheumatol 2001; 28: 2216-2221. Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F. “Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity”. Lupus 2001; 10: 554-561.

  21. Leaños-Miranda A, Pascoe-Lira D, Chávez-Rueda KA, Blanco-Favela F. “Antiprolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity”. J Rheumatol 2001, 28: 1546-1553.

  22. Rezaieyazdi Z, Hesamifard A. “Correlation between serum prolactin levels and lupus activity”. Rheumatol Int, 2006; 26: 1036-1039.

  23. McMurray RW, May W. “Sex hormones and systemic lupus erythematosus: review and meta-analysis”. Arthritis Rheum, 2003; 48: 2100-2110.

  24. Chuang E, Molitch ME. “Prolactin and autoimmune diseases in humans”. Acta Biomed 2007; 78 (Suppl 1): 255-261.

  25. Kramer CK, Tourinho TF, de Castro WP, da Costa Oliveira M. “Association between systemic lupus erythematosus, rheumatoid arthritis, hyperprolactinemia and thyroid autoantibodies”. Arch Med Res 2005; 36: 54-58.

  26. Walker SE. “Bromocriptine treatment of systemic lupus erythematosus”. Lupus, 2001 10:762-768.

  27. Vera-Lastra O, Mendez C, Jara LJ Cisneros M, Medina G, Ariza R, Espinoza LR. “Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment”. J Rheumatol 2003; 30(10): 2140-2146.

  28. Hrycek A, Pochopie´n-Kenig G, Scieszka J. “Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide”. Autoimmunity. 2007; 40: 217-222.

  29. Walker SE. “Impaired hypothalamic function, prolactinomas, and autoimmune diseases”. J Rheumatol 2006; 33: 1036-1037.

  30. Rezaieyazdi Z, Hesamifard A. “Correlation between serum prolactin levels and lupus activity”. Rheumatol Int 2006; 45: 97-101.

  31. Saha S, Tieng A, Pepeljugoski KP, Zandamn-Goddard G, Peeva E. “Prolactin, systemic lupus erythematosus and autorreactive B cells: lessons learnt from murine models”. Clin Rev Allergy Immunol 2011; 40(1): 8-15.

  32. Czuwara-Ladykowska J, Sicinska J, Olszewska M, Uhrynowska-Tyszkiewicz I, Rudnicka L. “Prolactin synthesis by lymphocytes from patients with systemic sclerosis”. Biomed Pharmacother. 2006; 60(4): 152-155.

  33. Mirone L, Barini A. “Androgen and prolactin (Prl) levels in systemic sclerosis (SSc): relationship to disease severity”. Ann N Y Acad Sci 2006; 1069: 257-262.

  34. Vera-Lastra O, Jara LJ, Medina G, Rojas JL, Veláquez F, Ariza R, Normandía A, Fuentes M. “Functional hyperprolactinemia and hypophyseal microadenoma in systemic sclerosis”. J Rheumatol 2006; 33(6): 1108-1112.

  35. Shahin AA, Abdoh S, Abdelrazik M. “Prolactin and thyroid hormones in patients with systemic sclerosis: correlations with disease manifestations and activity”. J Rheumatol 2002; 61: 703-709.

  36. Hilty C, Brühlmann P, Sprott H, Gay RE, Michel BA, Gay S, Neidhart M.H. “Altered diurnal rhythm of prolactin in systemic sclerosis”. J Rheumatol 2000 27:2160-2165.

  37. Weber G, Neidhardt M, Frey H, Galle K, Geiger A. “Treatment of psoriasis with bromocriptin”. Arch Dermatol 198; 271: 437-439.

  38. Foitzik K, Langan EA, Paus R. “Prolactin and the skin: a dermatological perspective on an ancient pleiotropic peptide hormone”. J Invest Dermatol 2009; 129(5): 1071-1087.

  39. Sanchez RM, Umbert MP. “Psoriasis in association with prolactinoma: three cases”. Br J Dermatol 2000; 143: 864-867.

  40. Dilmé-Carreras E, Martín-Ezquerra G, Sánchez-Regaña M, Umbert-Millet P. “Serum prolactin levels in psoriasis and correlation with cutaneous disease activity”. Clin Exp Dermatol. 2011; 36(1):29-32.

  41. El-Khateeb EA, Zuel-Fakkar NM, Eid SM, Abdul-Wahab SE. “Prolactin level is significantly elevated in lesional skin of patients with psoriasis”. Int J Dermatol 2011; 50(6): 693-696.

  42. Kanda N, Shibata S, Tada Y, Nashiro K, Tamaki K, Watanabe S. “Prolactin enhances basal and IL-17-induced CCL20 production by human keratinocytes”. Eur J Immunol 2009; 39(4): 996-1006.

  43. Haga HJ, Rygh T. “The prevalence of hyperprolactinemia in patients with primary Sjögren’s syndrome”. J Rheumatol 1999; 26: 1291-1295.

  44. El Miedany YM, Ahmed I, Moustafa H, El Baddini M. “Hyperprolactinemia in Sjogren’s syndrome: a patient subset or a disease manifestation?” Joint Bone Spine 2004; 71: 203-208.

  45. Steinfeld S, Rommes S, François C. “Big prolactin 60 kDa is overexpressed in salivary glandular epithelial cells from patients with Sjögren’s syndrome”. Lab Invest 2000; 80: 239-247.

  46. Johnson EO, Moutsopoulos HM. “Neuroendocrine manifestations in Sjögren’s syndrome. Relation to the neurobiology of stress”. Ann N Y Acad Sci 2000; 917: 797-808.

  47. Khandpur S, Reddy BS. “An unusual association of pemphigus vulgaris with hyperprolactinemia”. Int J Dermatol 2002; 41: 696-699.

  48. Fallahzadeh MK, Lashkarizadeh H, Kamali-Sarvestani E, Namazi MR. “Elevation of serum prolactin levels in patients with pemphigus vulgaris: a novel finding with practical implications”. J Am Acad Dermatol 2010; 62(6): 1071-1072.

  49. Schmidt JB. “Hormonal basis of male and female androgenic alopecia: clinical relevance”. Skin Pharmacol 1994; 7: 61–66.

  50. Friesen HG. “The discovery of human prolactin: a very personal account”. Clin Invest Med 1995; 18(1): 66-72.




2020     |     www.medigraphic.com